NASDAQ:BNTC Benitec Biopharma (BNTC) Stock Price, News & Analysis → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free BNTC Stock Alerts $8.15 -0.17 (-2.04%) (As of 05/7/2024 ET) Add Compare Share Share Today's Range$8.01▼$8.2850-Day Range$4.40▼$8.9552-Week Range$1.86▼$10.29Volume11,205 shsAverage Volume64,980 shsMarket Capitalization$21.11 millionP/E RatioN/ADividend YieldN/APrice Target$16.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Benitec Biopharma alerts: Email Address Benitec Biopharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside96.3% Upside$16.00 Price TargetShort InterestHealthy0.50% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.94 out of 5 starsMedical Sector626th out of 903 stocksPharmaceutical Preparations Industry288th out of 420 stocks 3.5 Analyst's Opinion Consensus RatingBenitec Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageBenitec Biopharma has only been the subject of 1 research reports in the past 90 days.Read more about Benitec Biopharma's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.50% of the float of Benitec Biopharma has been sold short.Short Interest Ratio / Days to CoverBenitec Biopharma has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Benitec Biopharma has recently increased by 10.91%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBenitec Biopharma does not currently pay a dividend.Dividend GrowthBenitec Biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BNTC. Previous Next 3.2 News and Social Media Coverage News SentimentBenitec Biopharma has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Benitec Biopharma this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for BNTC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Benitec Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Benitec Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.30% of the stock of Benitec Biopharma is held by insiders.Percentage Held by Institutions52.19% of the stock of Benitec Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Benitec Biopharma's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Book Value per Share RatioBenitec Biopharma has a P/B Ratio of 67.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Benitec Biopharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaIncredible Opportunity to Retire FAST!A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guide About Benitec Biopharma Stock (NASDAQ:BNTC)Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.Read More BNTC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BNTC Stock News HeadlinesMay 1, 2024 | finance.yahoo.comBenitec Biopharma to Participate in the Citizens JMP Life Science ConferenceApril 18, 2024 | msn.comWhy Is Gene Therapy Developer Benitec Biopharma Stock Trading Higher On Thursday?May 7, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. April 18, 2024 | finanznachrichten.deBenitec Biopharma Inc.: Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a StudyApril 18, 2024 | msn.comBenitec Biopharma jumps 33% on $40M private financingApril 18, 2024 | markets.businessinsider.comWhy Benitec Biopharma Is Rising In Pre-market?April 18, 2024 | globenewswire.comBenitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a StudyApril 18, 2024 | globenewswire.comBenitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 MillionMay 7, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. April 9, 2024 | finance.yahoo.comBenitec Biopharma to Host Virtual R&D Day to Discuss BB-301 Clinical Program in Oculopharyngeal Muscular Dystrophy on April 18, 2024March 24, 2024 | insidermonkey.com11 Best ASX Stocks To Buy NowFebruary 25, 2024 | msn.comBenitec Biopharma (BNTC) Price Target Increased by 66.67% to 10.20February 13, 2024 | finance.yahoo.comBenitec Biopharma Releases Second Quarter 2024 Financial Results and Provides Operational UpdateNovember 30, 2023 | finance.yahoo.comHere's Why Benitec Biopharma Inc.'s (NASDAQ:BNTC) CEO Compensation Is The Least Of Shareholders ConcernsNovember 30, 2023 | finance.yahoo.comBenitec Biopharma Announces First Subject Dosed in Phase 1b/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular DystrophyNovember 19, 2023 | morningstar.comBenitec Biopharma Inc BNTCNovember 17, 2023 | finance.yahoo.comBenitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare ConferenceNovember 15, 2023 | finanznachrichten.deBenitec Biopharma Inc.: Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational UpdateNovember 14, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Benitec Biopharma (BNTC), Rezolute (RZLT)November 13, 2023 | finance.yahoo.comBenitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational UpdateSeptember 27, 2023 | msn.comJMP Securities Maintains Benitec Biopharma (BNTC) Market Outperform RecommendationSeptember 26, 2023 | markets.businessinsider.comJMP Securities Sticks to Its Buy Rating for Benitec Biopharma (BNTC)September 21, 2023 | finance.yahoo.comBenitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational UpdateAugust 21, 2023 | finance.yahoo.comCitadel Advisors LLC Acquires New Stake in Benitec Biopharma IncAugust 11, 2023 | finance.yahoo.comBenitec Biopharma Inc. Announces Closing of $30 Million Underwritten Public OfferingAugust 9, 2023 | msn.comBenitec Biopharma prices $30M equity offeringAugust 9, 2023 | finance.yahoo.comBenitec Biopharma Inc. Announces Pricing of $30 Million Underwritten Public OfferingSee More Headlines Receive BNTC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Benitec Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/13/2024Today5/07/2024Next Earnings (Estimated)5/20/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BNTC CUSIPN/A CIK1808898 Webwww.benitec.com Phone510-780-0819Fax61 (0)3 9966-9923Employees16Year FoundedN/APrice Target and Rating Average Stock Price Target$16.00 High Stock Price Target$16.00 Low Stock Price Target$16.00 Potential Upside/Downside+99.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,560,000.00 Net MarginsN/A Pretax Margin-35,754.10% Return on Equity-204.34% Return on Assets-142.81% Debt Debt-to-Equity Ratio0.01 Current Ratio3.62 Quick Ratio3.62 Sales & Book Value Annual Sales$80,000.00 Price / Sales260.30 Cash FlowN/A Price / Cash FlowN/A Book Value$0.12 per share Price / Book67.00Miscellaneous Outstanding Shares2,590,000Free Float2,481,000Market Cap$20.82 million OptionableNo Data Beta0.80 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Jerel A. Banks M.D. (Age 49)Ph.D., Executive Chairman & CEO Comp: $848.07kMs. Megan Joan Boston BComm (Age 52)CA, Dip., GAICD, Executive Director Comp: $439.17kDr. Michael GrahamHead of Discovery & Founding ScientistDr. Claudia KlothSenior Vice President of ManufacturingKey CompetitorsTherapeuticsMDNASDAQ:TXMDFlora GrowthNASDAQ:FLGCRenovoRxNASDAQ:RNXTOncternal TherapeuticsNASDAQ:ONCTLisata TherapeuticsNASDAQ:LSTAView All Competitors BNTC Stock Analysis - Frequently Asked Questions Should I buy or sell Benitec Biopharma stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Benitec Biopharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BNTC shares. View BNTC analyst ratings or view top-rated stocks. What is Benitec Biopharma's stock price target for 2024? 1 Wall Street analysts have issued 12 month price targets for Benitec Biopharma's shares. Their BNTC share price targets range from $16.00 to $16.00. On average, they predict the company's stock price to reach $16.00 in the next twelve months. This suggests a possible upside of 96.3% from the stock's current price. View analysts price targets for BNTC or view top-rated stocks among Wall Street analysts. How have BNTC shares performed in 2024? Benitec Biopharma's stock was trading at $3.23 at the start of the year. Since then, BNTC stock has increased by 152.3% and is now trading at $8.15. View the best growth stocks for 2024 here. Are investors shorting Benitec Biopharma? Benitec Biopharma saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 12,200 shares, an increase of 10.9% from the March 31st total of 11,000 shares. Based on an average daily volume of 79,100 shares, the short-interest ratio is currently 0.2 days. Currently, 0.5% of the shares of the company are short sold. View Benitec Biopharma's Short Interest. When is Benitec Biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our BNTC earnings forecast. How were Benitec Biopharma's earnings last quarter? Benitec Biopharma Inc. (NASDAQ:BNTC) issued its quarterly earnings results on Tuesday, February, 13th. The biotechnology company reported ($2.64) earnings per share for the quarter. When did Benitec Biopharma's stock split? Benitec Biopharma's stock reverse split before market open on Wednesday, July 26th 2023. The 1-17 reverse split was announced on Wednesday, July 26th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 26th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. What other stocks do shareholders of Benitec Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Benitec Biopharma investors own include Amarin (AMRN), Pfizer (PFE), Amicus Therapeutics (FOLD), Sorrento Therapeutics (SRNE), Arbutus Biopharma (ABUS), Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Anavex Life Sciences (AVXL), BioLineRx (BLRX) and CRISPR Therapeutics (CRSP). When did Benitec Biopharma IPO? Benitec Biopharma (BNTC) raised $0 in an IPO on Thursday, August 6th 2015. The company issued 0 shares at $0.00 per share. BMO Capital Markets and Maxim Group LLC acted as the underwriters for the IPO and Roth Capital Partners was co-manager. Who are Benitec Biopharma's major shareholders? Benitec Biopharma's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. How do I buy shares of Benitec Biopharma? Shares of BNTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BNTC) was last updated on 5/7/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorElon Musk Secret Crypto Plot ExposedCrypto 101 MediaBiden replacement revealed?Paradigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsObama’s Forever Term [exposed]Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Benitec Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.